Ultherapy around the eye area

Of all the questions a traveler asks when she sits down for a consultation in Myeongdong, the eye area generates the most careful conversation, and the most disappointment when the explanation is rushed. The eye region is the zone where the face announces fatigue first — a brow that has descended half a millimetre, a tail of the eyebrow that has lost its lift, a soft hollow above the cheekbone that did not exist in the wedding photographs from ten years ago. It is also the zone where Ultherapy and the current Ultherapy PRIME generation do their most interesting work, and at the same time the zone where the platform's limitations have to be spoken about plainly, because the periorbital anatomy is unforgiving and the protocol around the eye is genuinely different from the protocol around the jawline. I want to walk through what the platform can do at the eye area — the 1.5 millimetre transducer for the dermis, the 3.0 millimetre transducer for the subdermal plane, the careful avoidance of the bony orbital rim, the realistic expectations for a brow lift, and the small but real possibility of transient periorbital swelling that the traveler should know about before she books a flight. The Merz Aesthetics platform has clearance for treatment of the brow area; what that clearance permits, how Korean physicians implement it, and what the published literature describes as a realistic outcome are the threads I pull through here.

Why the eye area is the zone where Ultherapy reads best

If the platform has a signature, it is the modest, slow lift it produces in the upper third of the face. The brow region responds to microfocused ultrasound for a reason that is mostly anatomical rather than commercial. The skin here is thin, the dermis sits close to the underlying tissue, and a small structural contraction in the dermis and the subdermal plane translates into a visible change at the surface that the same energy at the jawline would not produce. The published clinical observation across Merz Aesthetics technical documentation describes the brow lift as the most consistently demonstrable outcome of the platform — a one to two millimetre elevation of the lateral brow at twelve weeks. A millimetre sounds like nothing on paper. On a face, particularly on a face that has been photographed for years, it reads as a noticeable opening of the eye and a return to the brow the patient remembers from five or seven years ago. That is the platform's most reliable result, and it is why the eye area generates so much conversation in a Myeongdong consultation room.

The 1.5 mm focal point — what the dermal shots do

The 1.5 millimetre transducer delivers microfocused ultrasound to the dermis itself, the layer of skin between the visible surface and the subcutaneous tissue beneath. Each pulse creates a small thermal coagulation point inside the dermis — typically described in the technical literature as approximately one millimetre in dimension. These tiny dermal injuries trigger fibroblast activity in the layer of skin most directly responsible for surface tightness and elasticity. In the eye area, the 1.5 millimetre shots are concentrated across the brow itself, the lateral canthal region, and the periorbital skin above the orbital rim — but never on the eyelid proper, never inside the bony orbit, and never close enough to the lash line that the energy could touch the globe. Korean physicians tend to use the 1.5 millimetre transducer as the finishing layer of an eye-area protocol. The dermal contraction it produces complements the deeper structural lift the 3.0 millimetre shots are responsible for.

The 3.0 mm focal point — what the subdermal shots do

The 3.0 millimetre transducer delivers microfocused ultrasound to the subdermal plane — the layer beneath the dermis where the deeper supportive tissues of the face begin. In the eye area, these shots are the workhorse of the brow lift. They sit deep enough to engage the supportive connective tissue beneath the brow but shallow enough to remain safely above the bony orbital rim. The 3.0 millimetre transducer produces the small elevation of the lateral brow the published outcome data describes; without these shots, the platform would deliver dermal quality changes but not the structural lift patients come to the chair for. In a typical eye-area protocol, the 3.0 millimetre shots are distributed in a row above and slightly lateral to the brow, with the count varying but usually falling in the range of forty to sixty pulses for the bilateral brow region. The physician's depth selection and shot distribution matter more here than in any other anatomical zone.

The periorbital zones that should never be treated

This is the conversation I wish more clinics had with their patients before booking. Ultherapy and Ultherapy PRIME are not delivered onto the eyelid skin proper, not inside the bony orbital rim, and not in any zone where the energy could conceivably travel toward the globe. The 1.5 millimetre transducer can be used on the brow and the periorbital skin above the orbital rim, but not on the upper eyelid skin that sits on top of the orbit. The 3.0 millimetre transducer is used above the brow and laterally, not directly over the eye. No version of the protocol delivers shots onto the upper or lower eyelid skin, into the orbital fat compartments, or near the lacrimal apparatus. A clinic proposing shots onto the eyelid itself is operating outside the platform's clearance. I write this carefully because the eye-area conversation is sometimes garbled in translation, and an international patient who hears 'eye treatment' and pictures shots on the upper lid is picturing something the platform does not do and should not be asked to do.

The realistic brow lift — what a millimetre and a half looks like

The published clinical literature describes a typical lateral brow elevation at twelve weeks in the range of one to two millimetres, with considerable individual variation. A millimetre and a half is a small absolute measurement and a meaningful visible change. On a face, it reads as a slight opening of the eye, a return to the brow architecture the patient remembers from her younger photographs, a subtle softening of the tired set the upper third had developed. It does not read as a visibly different person. Friends notice the patient looks rested without identifying what changed. Patients who arrive expecting a brow position that mimics a surgical brow lift are arriving with the wrong reference image, and the honest Korean physician will say so during the consultation rather than agreeing to a protocol that cannot deliver what is being asked for.

The downtime calendar — day by day for the eye area

Downtime for an eye-area protocol follows the same pattern as the full-face platform with one or two periorbital specifics. Day of treatment: the brow region typically reads pink for two to four hours; some patients see faint swelling above the lateral brow where the 3.0 millimetre shots concentrated, resolving over twenty-four hours. Day one to day two: the brow region settles, sometimes with localised swelling visible to the patient but rarely to anyone else. Days three through seven: ordinary skincare resumes, makeup is fine from day one, SPF 50 or higher is essential in the first three days, and aggressive eye creams or retinoid products should pause for the first seven days. The lift itself develops between weeks four and twelve, with first visible change usually around week six and peak result around week twelve to sixteen. Bruising in the periorbital region is uncommon but more visible when it does occur because the skin here is thin; it usually resolves over five to ten days without intervention.

Why patients sometimes ask about Botox at the same consultation

The brow-area conversation in Myeongdong often touches on whether the patient should also be considering neuromodulators in the upper third of the face. The two treatments work on different mechanisms — Ultherapy creates structural collagen remodelling in the dermal and subdermal layers, while neuromodulators temporarily relax the muscles that pull the brow downward. Patients with significant frown-line activity or with a brow position actively pulled down by the corrugator and procerus muscles often benefit from a neuromodulator conversation alongside the Ultherapy conversation; the two can complement each other when used appropriately. This is an observation, not a recommendation. The clinical decision belongs with the treating physician, who can assess whether the brow responds primarily to a structural intervention, a muscular one, or both.

How to ask a Myeongdong clinic about the eye-area protocol

When the consultation reaches the eye area, the practical questions are specific. Ask which transducer depths will be used — the answer should reference 1.5 millimetres and 3.0 millimetres. Ask how the protocol avoids the orbital rim and the eyelid skin proper; the answer should be detailed and confident, not vague. Ask the approximate shot count for the brow region — a typical bilateral brow protocol falls between forty and sixty pulses at 3.0 millimetres plus a dermal layer at 1.5 millimetres. Ask whether the clinic is operating original Ultherapy or the current Ultherapy PRIME generation; both deliver competent eye-area work, but PRIME's faster pulse delivery is the current standard. Ask to see a sketch of the proposed shot map. The clinics that have been treating international patients for a decade engage this kind of questioning openly; the clinics that prefer to move quickly past the technical conversation are not the consultations a traveler should be relying on.

Frequently asked questions

Can Ultherapy be used on my upper eyelids?

No. The platform is delivered onto the brow region and the periorbital skin above the bony orbital rim, but not onto the upper or lower eyelid skin itself. Any clinic proposing shots onto the eyelid proper is operating outside the platform's clearance and outside published safety guidance.

What kind of brow lift can I realistically expect?

Published clinical literature describes a lateral brow elevation in the range of one to two millimetres at twelve weeks for typical patients, with considerable individual variation. The visual effect reads as a slight opening of the eye and a softening of the tired set the upper third had developed, rather than as a visibly different face.

Which transducer depths are used around the eye area?

The 1.5 millimetre transducer delivers dermal-level shots for skin quality, and the 3.0 millimetre transducer delivers subdermal shots that produce the structural lift. The deeper 4.5 millimetre transducer used in other facial zones is not used in the periorbital region.

Will I have bruising around the eyes?

Bruising in the periorbital region is uncommon but more visible when it does occur because the skin here is thin. When it happens it usually resolves over five to ten days without intervention. Most patients have no visible bruising at the eye area at all.

How long before the eye-area lift is visible?

First visible change usually appears between weeks four and six. The result peaks between three and four months as collagen remodelling matures. Photograph at baseline and at six weeks in the same lighting and angle to track the change reliably.

Can I wear eye makeup after the treatment?

Yes, from day one. The skin surface is intact and ordinary cosmetics do not interact with the treatment. Pause aggressive eye-area actives — strong retinoids, glycolic acid eye serums — for the first seven days, then resume.

Is the eye-area treatment painful?

Topical anaesthesia is applied for thirty to forty-five minutes before treatment. The brow region tends to register the shots more sharply than the jawline because the bone sits closer to the surface; most patients describe it as brief and tolerable rather than truly painful. Tell the operating physician if any single shot reads as too intense — the protocol can be adjusted.

Can I combine the eye-area treatment with Botox in the same trip?

Yes, the two are commonly discussed in the same consultation. They work on different mechanisms — Ultherapy on collagen remodelling, neuromodulators on muscular activity — and can complement each other in the upper third of the face. The clinical decision about whether both are appropriate belongs with the treating physician.